The popularity of Sildenafil initially fueled a boom for pharma, nevertheless recent changes present a murky outlook for those considering a stake. Off-patent versions are eroding revenue, and persistent legal battles add more difficulty to the landscape. While specific companies could still see gains from complementary services, the general trend